PT  - JOURNAL ARTICLE
AU  - Gert Jacobus Laubscher
AU  - Petrus Johannes Lourens
AU  - Chantelle Venter
AU  - Lize Mireille Grobbelaar
AU  - Douglas B Kell
AU  - Etheresia Pretorius
TI  - A decision-tree approach to treat platelet hyperactivity and anomalous blood clotting in acute COVID-19 patients
AID  - 10.1101/2021.07.05.21260012
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.05.21260012
4099  - http://medrxiv.org/content/early/2021/07/25/2021.07.05.21260012.short
4100  - http://medrxiv.org/content/early/2021/07/25/2021.07.05.21260012.full
AB  - The coronavirus disease 2019 (COVID-19) (SARS-Cov-2) has caused a worldwide, sudden and substantial increase in hospitalizations for pneumonia with multiorgan problems. An important issue is also that there is still no unified standard for the diagnosis and treatment of COVID-19. Substantial vascular events are significant accompaniments to lung complications in COVID-19 patients. Various papers have now also shown the significance of thromboelastrography (TEG®) as point-of-care technology to determine the levels of coagulopathy (both clotting and bleeding) in COVID-19, in managing COVID-19 patients. Here we present two treatment protocols that may used to treat thrombotic and bleeding or thrombocytopenia pathologies. Both the protocols use clinical parameters like D-dimer and CRP, as well as the TEG®, to closely follow the daily clotting propensity of COVID-19 patients. We conclude by suggesting that the treatment of COVID-19 patients, should be based on a combination of blood biomarkers, and results from point-of-care analyses like the TEG®. Such a combination approach closely follow the physiological responses of the immune system, the haematological, as well as the coagulation system, in real-time.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementDBK thanks the Novo Nordisk Foundation for financial support (grant NNF20CC0035580). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human ethics Committee: Stellenbosch UniversityAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A